22353-40-8

Usage

Chemical Properties

Light yellow Cryst

Upstream product

• 22353-38-4 3-chloro-2-hydroxy-5-nitropyridine 
• 10025-87-3 trichlorophosphate 
• 5418-51-9 5-nitro-2-hydroxypyridine 

Downstream Products

• 64007-60-9 3-chloro-5-nitro-pyridine-2-thiol 
• 951771-92-9 (3-chloro-5-nitro-pyridin-2-yl)-(4-chloro-phenyl)-amine 
• 940303-07-1 3-chloro-5-nitro-2-[3-(trifluoromethyl)phenoxy]pyridine 
• 488713-30-0 3-chloro-5-nitropyridine-2-carbonitrile 
• 488713-31-1 5-amino-3-chloro-2-cyanopyridine 
• 59-49-4 2-Benzoxazolinone 
• 22353-38-4 3-chloro-2-hydroxy-5-nitropyridine 
• 1013695-70-9 2,4-dichloro-N-(5-chloro-6-(isoquinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide 
• 1654021-72-3 ((5,6-dichloro-2-cyanopyridin-3-yl)oxy)acetic acid ethyl ester 

Relevant academic research and scientific papers

PYRIDYL COMPOUND SUITABLE FOR THE TREATMENT OF METABOLIC DISORDERS

The description relates to a pyridyl compound of Formula 1 wherein A, B, X, R1, R2, R3, R4, R5, R6, and n are as defined in the specification, in all their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, their pharmaceutically acceptable salts, N-oxides, pharmaceutically acceptable solvates, isosteres and prodrugs thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The description also relates to a process for the manufacture of the pyridyl compound and a pharmaceutical composition containing the pyridyl compound.

STABLE ORAL TABLET DOSAGE FORM OF AN ANTIDIABETIC COMPOUND

The invention relates to a stable oral tablet dosage form comprising an antidiabetic compound (a compound of formula (I) or a pharmaceutically acceptable salt thereof) as the active pharmaceutical ingredient, a non-ionic surfactant and one or more pharmac

Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl) benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist

The thiazolidinediones (TZDs) are a class of oral antidiabetic drugs that improve insulin sensitivity in patients with type 2 diabetes. Although the mechanism by which the TZDs lower insulin resistance is unclear, they are known to target the peroxisome p

METHOD FOR IDENTIFYING COMPOUNDS THAT ACT AS INSULIN-SENSITIZERS

The present invention relates to a method for identifying compounds that act as insulin-sensitizers. The method can include screening of test compounds in two assays of insulin sensitivity. This method can identify lead compounds for the treatment of disorders caused by insulin resistance to glucose uptake. This invention also includes methods for treating insulin resistance and related disorders.

3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS

The picsenl invention provides novel compounds represented by the general formula (I): wherein Ar is a quinoline or isoquinoline moiety which is substituted or unsubstituted; B is -O. -S-. or -NH-: R1 is hydrogen or S(O)2R4: R2 is S(O)2R4. C(O)OR5. or C(O

KINASE INHIBITORS

The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.

(1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate

The present invention relates to the salt (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate and to methods of preparing the salt.

AMINE-LINKED PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having th

(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent

The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.